Compare Phillips 66 (PSX) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Phillips 66 vs Recursion Pharmaceuticals Inc — how do they compare? Phillips 66 trades at $278 (market cap $112.36B), while Recursion Pharmaceuticals Inc trades at $4.35 (market cap $2.14B). The key difference: Phillips 66 is far larger — about 52.5× Recursion Pharmaceuticals Inc's market cap, and Phillips 66 pays a 1.8% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Phillips 66 for 62 Days and Recursion Pharmaceuticals Inc for 23 Days on average.
| PSX | RXRX | |
|---|---|---|
Market Cap | $112.36B | $2.14B |
Volume | 2,374,751 | 30,789,535 |
Sector | Energy | Health |
52-Week High | $281.60 | $6.79 |
52-Week Low | $126.76 | $2.84 |
Typical Hold Time | 62 Days | 23 Days |
Enterprise Value | $128.83B | $1.66B |
Dividend Yield | 1.8% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Phillips 66 (PSX) trades at $278.18, up 2.42% with strong technical momentum as it approaches resistance near $280. The stock shows robust fundamentals with a P/E of 16.07 and ROE of 24.02%, supported by three consecutive earnings beats. Recent news highlights structural refining advantages and AI-driven operational improvements, while analyst consensus remains bullish with a $279 price target.
PSX offers attractive valuation metrics and strong profitability, though revenue declines from 2022-2025 present headwinds. Key risks include refining margin volatility and potential diesel export restrictions. With institutional support and positive earnings trajectory, the stock presents a compelling opportunity for value-oriented investors despite cyclical industry exposure.
RXRX trades at $4.255, down 0.35% on the day, with a bullish technical signal from moving averages. The company reported a net loss of $644.76 million in 2025 on $74.26 million revenue, with a negative net income margin of -961.97%. Recent news highlights strategic AI partnerships, including an extended data license with Tempus AI announced September 21, 2026, and pipeline progress presented at the Morgan Stanley Healthcare Conference.
The outlook remains speculative, driven by AI-powered drug discovery potential and partnership milestones, but significant execution risk persists due to heavy losses and high cash burn. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for long-term platform value against near-term financial challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Phillips 66
Phillips 66 is an independent refiner with 12 refineries that have a total crude throughput capacity of 2.0 million barrels per day, or mmb/d, after converting its 255 mb/d Alliance refinery to a terminal. The midstream segment comprises extensive transportation and NGL processing assets. It also includes its DCP Midstream joint venture, which holds 45 natural gas processing facilities, 11 NGL fractionation plants, and a natural gas pipeline system with 58,000 miles of pipeline. Its CPChem chemical joint venture operates facilities in the United States and the Middle East and primarily produces olefins and polyolefins.
Read more on PSX →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
